Aldosterone synthase inhibitors reduced aldosterone levels, lowered systolic and diastolic blood pressure, and decreased albuminuria in patients with primary aldosteronism.
Do aldosterone synthase inhibitors reduce blood pressure and albuminuria in patients with primary aldosteronism, resistant hypertension, and chronic kidney disease?
Next-generation aldosterone synthase inhibitors offer a mechanistically coherent strategy to suppress residual aldosterone activity, showing promise in early trials for resistant hypertension and chronic kidney disease.
Absolute Event Rate: 0% vs 0%
Abstract Excess aldosterone is a key driver of cardiovascular, renal, and metabolic injury, promoting hypertension, myocardial fibrosis, proteinuria, and progressive chronic kidney disease (CKD). Conventional therapies, renin–angiotensin–aldosterone system (RAAS) inhibitors, and mineralocorticoid receptor antagonists attenuate downstream receptor signaling but do not suppress aldosterone biosynthesis, allowing residual hormonal activity that perpetuates tissue damage. The long‐term efficacy, endocrine selectivity, and clinical significance of directly inhibiting aldosterone synthesis, however, remain only partly defined, particularly with respect to sustained aldosterone suppression, preservation of cortisol production, and applicability across diverse cardiorenal disorders. This review provides a comprehensive and mechanistically focused synthesis of preclinical and clinical evidence on aldosterone synthase inhibitors (ASIs), examining their pharmacologic specificity, hormonal effects, and emerging therapeutic potential in primary aldosteronism (PA), resistant hypertension, and CKD. Next‐generation ASIs—including baxdrostat, lorundrostat, dexfadrostat phosphate, and vicadrostat—demonstrate >100‐fold selectivity for CYP11B2 over CYP11B1, enabling potent and reversible aldosterone suppression while maintaining cortisol biosynthesis. Across early‐phase trials, these agents consistently reduce aldosterone concentrations, lower systolic and diastolic blood pressure, decrease albuminuria, and normalize potassium balance in PA, with favorable safety and minimal hypothalamic–pituitary–adrenal axis disturbance. Collectively, these findings position ASIs as a selective and mechanistically coherent therapeutic strategy that addresses residual aldosterone activity beyond conventional RAAS blockade. Although current evidence relies largely on surrogate endpoints, ongoing phase III outcome trials will determine whether ASIs can translate mechanistic promise into durable cardiovascular and renal protection, potentially redefining the therapeutic landscape of aldosterone‐mediated diseases.
Merlo et al. (Mon,) reported a other. Aldosterone synthase inhibitors reduced aldosterone levels, lowered systolic and diastolic blood pressure, and decreased albuminuria in patients with primary aldosteronism.